REGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingFDAFDA advisory committee meetings scheduled: late July 2026RESEARCHTranslational Health Research Into Vascular and Neurocognitive Effects of Weight Loss [NCT07592546]RESEARCHA Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) [NCT07165028]RESEARCHTirzepatide in the Treatment of Endometrial Cancer [NCT07605247]RESEARCHA Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan [NCT06635057]RESEARCHA Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide [NCT06897475]RESEARCHA Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature [NCT06382155]RESEARCHMetabolic Effects of Angiotensin-(1-7) [NCT02646475]RESEARCHMulti-Site Trial of Tirzepatide for Smoking Cessation [NCT07602699]RESEARCHEvaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder [NCT06651177]NEWSOorja, run by Acceleron veterans, launches to make new fibrosis drugsREGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingFDAFDA advisory committee meetings scheduled: late July 2026RESEARCHTranslational Health Research Into Vascular and Neurocognitive Effects of Weight Loss [NCT07592546]RESEARCHA Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) [NCT07165028]RESEARCHTirzepatide in the Treatment of Endometrial Cancer [NCT07605247]RESEARCHA Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan [NCT06635057]RESEARCHA Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide [NCT06897475]RESEARCHA Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature [NCT06382155]RESEARCHMetabolic Effects of Angiotensin-(1-7) [NCT02646475]RESEARCHMulti-Site Trial of Tirzepatide for Smoking Cessation [NCT07602699]RESEARCHEvaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder [NCT06651177]NEWSOorja, run by Acceleron veterans, launches to make new fibrosis drugs

For research purposes only. Full disclaimer →

Stack Library

Russian Brain Stack

Cognitive Enhancementintermediate

88

synergy

88
Share
Peptides

2

Avg Daily mcg

900

Level

intermediate

Added

May 17, 2026

Overview

The Russian Brain Stack is one of the most pharmacologically elegant peptide combinations in the longevity and cognitive optimization space. Both Semax and Selank were developed at the Institute of Molecular Genetics of the Russian Academy of Sciences and have been prescribed in Russia and Eastern Europe for decades for cognitive enhancement, anxiety, and neurological conditions. Their combination earns a synergy score of 88/100. Semax is a synthetic heptapeptide analog of ACTH (adrenocorticotropic hormone) fragment 4-7. It powerfully upregulates BDNF (Brain-Derived Neurotrophic Factor) — the primary growth factor for neurons — and enhances dopaminergic and serotonergic signaling. The practical effects are significant: improved focus, working memory, learning speed, and mental clarity. It also demonstrates neuroprotective properties, reducing oxidative stress and inflammation in neural tissue. Selank is a synthetic analog of the endogenous tetrapeptide tuftsin, with added stability for intranasal delivery. It modulates GABA signaling and serotonin systems to produce anxiolytic (anti-anxiety) effects without sedation or dependence. Unlike benzodiazepines, Selank does not impair cognition — it enhances it while reducing the anxiety and stress that typically interfere with focus and performance. The synergy is complementary by design: Semax provides the cognitive upregulation (BDNF, focus, memory) while Selank provides the anxiolytic stabilization (calm, reduced cortisol reactivity, stress resilience). Together, they produce a state of calm, focused, high-performance cognition — alertness without anxiety, focus without jitteriness — that neither achieves alone. Both are administered intranasally, which provides efficient CNS delivery without first-pass metabolism.

Dosing Protocol

Semax

Every day· intranasal

Read more about Semax →

600 mcg

per dose

Selank

Every day· intranasal

Read more about Selank →

300 mcg

per dose

Goals & Evidence

Focus and concentrationMemory and learningAnxiety reductionCalm cognitionNeuroplasticity
Evidence tier:Human Data

Warnings

  • Semax and Selank are prescription medications in Russia. Regulatory status varies by country. Not FDA-approved in the US.

Comments

Sign in to join the discussion

Disclaimer: This stack is community-submitted and for research purposes only. Peptide Contacts does not verify the safety or efficacy of submitted stacks. Always consult a qualified healthcare professional before using any peptide protocol.